ATRC Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
154.4M
+0.6%
153.6M
+8.7%
141.2M
+0.5%
140.5M
+4.6%
134.3M
Cost of Revenue
35.1M
+0.4%
35.0M
+9.5%
31.9M
-9.2%
35.2M
+6.8%
32.9M
Gross Profit
119.3M
+0.6%
118.6M
+8.5%
109.3M
+3.8%
105.3M
+4.0%
101.3M
Operating Expenses
115.0M
+5.5%
109.0M
+0.2%
108.8M
+5.8%
102.8M
+1.7%
101.1M
R&D
32.1M
+21.6%
26.4M
+8.9%
24.2M
-1.1%
24.5M
+7.0%
22.9M
SG&A
82.9M
+0.4%
82.6M
-2.4%
84.5M
+7.9%
78.3M
+0.1%
78.2M
Operating Income
4.4M
-55.0%
9.7M
+1737.5%
526.0K
-78.9%
2.5M
+1097.6%
208.0K
EBITDA
9.8M
-34.4%
15.0M
+158.2%
5.8M
-23.7%
7.6M
+41.3%
5.4M
Net Income
4.1M
-54.6%
9.0M
+8191.7%
108.0K
-93.8%
1.8M
+757.7%
-267000
EPS (Basic)
$0.08
-55.6%
$0.18
$0.00
-100.0%
$0.04
+500.0%
$-0.01
EPS (Diluted)
$0.08
-55.6%
$0.18
$0.00
-100.0%
$0.04
+500.0%
$-0.01
Shares (Diluted)
49.8M
+2.0%
48.9M
-0.4%
49.0M
+2.3%
48.0M
+0.1%
47.9M
AtriCure (ATRC) — Financials